TOMI Environmental Solutions, Inc. Partners with Pharma Biotech System Components to Enhance Disinfection Solutions
TOMI Environmental Solutions (NASDAQ: TOMZ) has announced an OEM partnership with Pharma Biotech System Components (PBSC) to enhance its SteraMist Integrated System (SIS) product line. Through this collaboration, TOMI will offer pass-through hatches and chambers integrated with iHP technology for optimized decontamination cycles.
PBSC, a leading manufacturer of cleanroom and high containment solutions, serves pharmaceutical, medical research, and hospital sectors worldwide. The partnership leverages PBSC's expertise in high-containment enclosures while expanding SteraMist adoption in critical industries. Several projects are currently in progress, demonstrating strong market demand for this innovative system.
The partnership enhances TOMI's Binary Ionization Technology® (BIT™) platform, which uses low percentage hydrogen peroxide and patented ionized Hydrogen Peroxide (iHP™) technology for superior disinfection across various sectors including hospitals, biosafety labs, and pharmaceutical facilities.
TOMI Environmental Solutions (NASDAQ: TOMZ) ha annunciato una partnership OEM con Pharma Biotech System Components (PBSC) per migliorare la sua linea di prodotti SteraMist Integrated System (SIS). Grazie a questa collaborazione, TOMI offrirà aperture e camere passanti integrate con tecnologia iHP per ottimizzare i cicli di decontaminazione.
PBSC, un produttore leader di soluzioni per camere bianche e alta contenimento, serve i settori farmaceutico, della ricerca medica e degli ospedali in tutto il mondo. La partnership sfrutta l'esperienza di PBSC nelle strutture ad alta contenimento, ampliando al contempo l'adozione di SteraMist in settori critici. Attualmente sono in corso diversi progetti, che dimostrano una forte domanda di mercato per questo sistema innovativo.
La partnership potenzia la piattaforma Binary Ionization Technology® (BIT™) di TOMI, che utilizza una bassa percentuale di perossido di idrogeno e la tecnologia brevettata di Perossido di Idrogeno Ionizzato (iHP™) per una disinfezione superiore in vari settori, tra cui ospedali, laboratori di biosicurezza e strutture farmaceutiche.
TOMI Environmental Solutions (NASDAQ: TOMZ) ha anunciado una asociación OEM con Pharma Biotech System Components (PBSC) para mejorar su línea de productos SteraMist Integrated System (SIS). A través de esta colaboración, TOMI ofrecerá compuertas y cámaras de paso integradas con tecnología iHP para ciclos de descontaminación optimizados.
PBSC, un fabricante líder de soluciones de salas limpias y alta contención, atiende a los sectores farmacéutico, de investigación médica y hospitales en todo el mundo. La asociación aprovecha la experiencia de PBSC en recintos de alta contención mientras expande la adopción de SteraMist en industrias críticas. Actualmente, varios proyectos están en curso, lo que demuestra una fuerte demanda del mercado para este sistema innovador.
La asociación mejora la plataforma Binary Ionization Technology® (BIT™) de TOMI, que utiliza un bajo porcentaje de peróxido de hidrógeno y la tecnología patentada de Peróxido de Hidrógeno Ionizado (iHP™) para una desinfección superior en varios sectores, incluidos hospitales, laboratorios de bioseguridad y instalaciones farmacéuticas.
TOMI Environmental Solutions (NASDAQ: TOMZ)는 SteraMist Integrated System (SIS) 제품 라인을 강화하기 위해 Pharma Biotech System Components (PBSC)와 OEM 파트너십을 발표했습니다. 이번 협력을 통해 TOMI는 최적화된 오염 제거 사이클을 위한 iHP 기술이 통합된 통과 해치와 챔버를 제공합니다.
PBSC는 청정실 및 고밀폐 솔루션의 선두 제조업체로, 전 세계의 제약, 의료 연구 및 병원 분야에 서비스를 제공합니다. 이 파트너십은 PBSC의 고밀폐 인클로저에 대한 전문성을 활용하면서 SteraMist의 채택을 중요한 산업으로 확장합니다. 현재 여러 프로젝트가 진행 중이며, 이 혁신적인 시스템에 대한 강력한 시장 수요를 보여줍니다.
이 파트너십은 TOMI의 Binary Ionization Technology® (BIT™) 플랫폼을 강화하며, 이는 저농도 과산화수소와 특허받은 이온화 과산화수소(iHP™) 기술을 사용하여 병원, 생물안전 연구소 및 제약 시설을 포함한 다양한 분야에서 우수한 소독을 제공합니다.
TOMI Environmental Solutions (NASDAQ: TOMZ) a annoncé un partenariat OEM avec Pharma Biotech System Components (PBSC) pour améliorer sa gamme de produits SteraMist Integrated System (SIS). Grâce à cette collaboration, TOMI proposera des trappes et des chambres de passage intégrées avec la technologie iHP pour des cycles de décontamination optimisés.
PBSC, un fabricant leader de solutions pour salles blanches et haute contenance, sert les secteurs pharmaceutique, de la recherche médicale et des hôpitaux dans le monde entier. Ce partenariat tire parti de l'expertise de PBSC en matière d'enceintes à haute contenance tout en élargissant l'adoption de SteraMist dans des industries critiques. Plusieurs projets sont actuellement en cours, démontrant une forte demande du marché pour ce système innovant.
Ce partenariat renforce la plateforme Binary Ionization Technology® (BIT™) de TOMI, qui utilise un faible pourcentage de peroxyde d'hydrogène et la technologie brevetée de Peroxyde d'Hydrogène Ionisé (iHP™) pour une désinfection supérieure dans divers secteurs, y compris les hôpitaux, les laboratoires de biosécurité et les installations pharmaceutiques.
TOMI Environmental Solutions (NASDAQ: TOMZ) hat eine OEM-Partnerschaft mit Pharma Biotech System Components (PBSC) angekündigt, um seine Produktlinie SteraMist Integrated System (SIS) zu verbessern. Durch diese Zusammenarbeit wird TOMI Durchgangsöffnungen und Kammern anbieten, die mit iHP-Technologie für optimierte Dekontaminationszyklen integriert sind.
PBSC, ein führender Hersteller von Reinraumsystemen und Hochsicherheitslösungen, bedient weltweit die pharmazeutische, medizinische Forschungs- und Krankenhausbranche. Die Partnerschaft nutzt PBSCs Fachwissen in Hochsicherheitsgehäusen und erweitert gleichzeitig die Einführung von SteraMist in kritischen Industrien. Derzeit sind mehrere Projekte in Arbeit, die eine starke Marktnachfrage nach diesem innovativen System zeigen.
Die Partnerschaft verbessert die Binary Ionization Technology® (BIT™) Plattform von TOMI, die einen niedrigen Anteil an Wasserstoffperoxid und die patentierte ionisierte Wasserstoffperoxid (iHP™) Technologie für eine überlegene Desinfektion in verschiedenen Sektoren, einschließlich Krankenhäuser, Biosicherheitslabore und pharmazeutische Einrichtungen, verwendet.
- Strategic OEM partnership expands product offering with high-containment solutions
- Multiple ongoing projects demonstrate strong market demand
- Enhanced market access to pharmaceutical and medical research sectors
- None.
Insights
TOMI's new OEM partnership with PBSC represents a strategic enhancement to their disinfection technology ecosystem. By integrating their SteraMist iHP technology into PBSC's pass-through hatches and chambers, TOMI addresses a critical contamination control pain point in pharmaceutical manufacturing and research environments.
This collaboration effectively combines TOMI's proprietary ionized Hydrogen Peroxide technology (developed under a DARPA research grant) with PBSC's specialized containment infrastructure. The partnership has significant implementation potential across pharmaceutical facilities, research laboratories, and hospitals where maintaining sterile environments is mission-critical.
The announcement of "several projects currently underway" suggests immediate market validation and adoption. For TOMI, with its relatively small market capitalization (
This partnership strategically positions TOMI's technology deeper into highly regulated workflows where contamination control demands are exceptionally stringent. While financial terms weren't disclosed, this integration approach should accelerate deployment opportunities compared to developing complete systems independently.
This partnership represents a high-value technical integration that addresses specific contamination control challenges in controlled environments. PBSC's pass-through chambers are critical infrastructure components in cleanroom operations, serving as transfer points that typically represent vulnerability in contamination control workflows.
By embedding TOMI's SteraMist technology directly into these transfer systems, the partnership creates a more seamless decontamination process for materials moving between different classification zones. The SteraMist iHP approach provides significant advantages over traditional vapor hydrogen peroxide (VHP) systems through its ionization mechanism, which enhances distribution and efficacy particularly in complex geometries.
For facilities maintaining ISO-classified environments or operating under GMP regulations, this integrated solution potentially reduces validation complexity compared to standalone decontamination processes. The OEM arrangement suggests PBSC recognizes the technical differentiation of TOMI's approach.
What's particularly notable is that this partnership demonstrates TOMI's shift toward embedded systems integration rather than just standalone equipment sales. This strategy typically provides more sustainable revenue opportunities and deeper client relationships across the pharmaceutical, medical research, and hospital sectors mentioned in the announcement.
FREDERICK, Md., March 25, 2025 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a leader in disinfection and decontamination solutions, today announced an OEM partnership with Pharma Biotech System Components LLC/Pharma Biotech System Components Ltd (PBSC), a premier manufacturer specializing in high containment, material decontamination, and cleanroom solutions. This collaboration enhances TOMI's SteraMist Integrated System (SIS) product launched in the second half of last year. Through this OEM agreement, TOMI will now offer pass-through hatches and chambers integrated with iHP, specifically designed for optimized decontamination cycles.
PBSC is one of the leading manufacturers of Cleanroom, High Containment, and Material Decontamination products worldwide, offering an extensive product range, bespoke designs, and assembly capabilities. Catering to the needs of customers with high-quality products and services within the Pharmaceutical, Medical Research, high Containment, and Hospital sectors around the world.
This partnership enables TOMI to leverage PBSC’s expertise in high-containment enclosures while expanding the adoption of SteraMist in critical industries. Through integration with PBSC’s designs, TOMI’s SIS provides an efficient method for achieving high-level disinfection in critical environments. Several projects are currently underway, showcasing the strong market demand for this innovative system.
"We are excited to formalize our partnership with PBSC," said Elissa J. (E.J.) Shane, COO of TOMI Environmental Solutions. "This agreement represents a significant advancement in fulfilling the increasing demand for iHP-integrated disinfection solutions. We are experiencing strong interest and are actively marketing and bidding on projects utilizing SIS products and high-quality pass-through hatches and chambers offered by PBSC."
TOMI™ Environmental Solutions, Inc.: Innovating for a safer world®
TOMI™ Environmental Solutions, Inc. (NASDAQ: TOMZ) is a global decontamination and infection prevention company, providing environmental solutions for disinfection through the manufacturing, sales and licensing of its premier Binary Ionization Technology® (BIT™) platform. Invented under a defense grant in association with the Defense Advanced Research Projects Agency (DARPA) of the U.S. Department of Defense, BIT™ solution utilizes a low percentage hydrogen peroxide as its only active ingredient and uses patented ionized Hydrogen Peroxide (iHP™) technology in all SteraMist systems to create superior disinfection. TOMI products are designed to service a broad spectrum of use sites, including, but not limited to, hospitals and medical facilities, biosafety labs, pharmaceutical facilities, commercial and office buildings, schools, restaurants, meat and produce processing facilities, and police and fire departments.
For additional information, please visit http://www.steramist.com or contact us at info@tomimist.com
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995
This press release contains forward-looking statements that are based on current expectations, estimates, forecasts and projections of future performance based on management’s judgment, beliefs, current trends, and anticipated product performance. These forward-looking statements include, without limitation, statements relating to TOMI’s products to serve life science sectors. Forward-looking statements involve risks and uncertainties that may cause actual results to differ materially from those contained in the forward-looking statements. These factors include, but are not limited to, our ability to maintain and manage growth and generate sales, our reliance on a single or a few products for a majority of revenues; the general business and economic conditions; and other risks as described in our SEC filings, including our Annual Report on Form 10-K for the fiscal year ended December 31, 2023 filed by us with the SEC and other periodic reports we filed with the SEC. The information provided in this document is based upon the facts and circumstances known at this time. Other unknown or unpredictable factors or underlying assumptions subsequently proving to be incorrect could cause actual results to differ materially from those in the forward-looking statements. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, level of activity, performance, or achievements. You should not place undue reliance on these forward-looking statements. All information provided in this press release is as of today’s date, unless otherwise stated, and we undertake no duty to update such information, except as required under applicable law.
INVESTOR RELATIONS CONTACT:
John Nesbett/Rosalyn Christian
IMS Investor Relations
tomi@imsinvestorrelations.com
FAQ
What is the significance of TOMI's (TOMZ) partnership with PBSC?
How will the PBSC partnership affect TOMI's (TOMZ) market reach?
What technology does TOMI (TOMZ) use in its disinfection systems?
What is the current status of TOMI's (TOMZ) SteraMist Integrated System projects?
